Nayzilam Generic Name & Formulations
Nayzilam Dosage and Administration
Nayzilam Boxed Warnings
Increased risk of drug-related mortality from concomitant use with opioids. Decreased pulmonary reserve. COPD. Monitor for the emergence or worsening of depression, suicidal thoughts/behavior, and/or unusual changes in mood or behavior. Open-angle glaucoma. Impaired cognitive function. Obesity. CHF. Assess patient's risk for abuse, misuse, addiction prior to and during therapy. Avoid abrupt cessation. Withdraw gradually. Drug or alcohol abusers. Hepatic or moderate to severe renal impairment. Elderly. Debilitated. Neonatal sedation and withdrawal syndrome; monitor neonates exposed during pregnancy or labor. Pregnancy (esp. late stage). Nursing mothers: monitor infants.
Midazolam is ~97% bound to plasma protein, principally albumin. In healthy volunteers, 1-hydroxy midazolam is bound to the extent of 89%.
The estimated total volume of distribution of midazolam is 226.5 L.
Renal. Half-life: 2.1–6.2 hours (midazolam); and 2.7–7.2 hours (1-hydroxy midazolam).
Nayzilam Adverse Reactions
Nayzilam Clinical Trials
Nayzilam Patient Counseling